The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer.
Ayaka KatayamaJane StarczynskiMichael S TossAbeer M ShaabanElena ProvenzanoCecily M QuinnGrace CallagyColin A PurdieRebecca Millican-SlaterDavid PurnellLeena ChaglaTetsunari OyamaSarah E PinderSteve ChanIan EllisAndrew H S LeeEmad A RakhaPublished in: Histopathology (2022)
The impacts of CEP17 alterations are not as strong as those of HER2/CEP17 ratio and HER2 copy number. The hormonal receptors status and tumour histological grade are more useful to identify BC patients with a HER2 immunohistochemistry-equivocal score who would benefit from NAT.